“Far from a dead company, this may be one of the best held secrets in the biotech landscape,” declares the author of today’s article of the little-followed biotechnology company they highlight: an “antibody discovery company that could have the potential to revolutionize the process for discovering and rapidly advancing new therapies.” For more, CLICK HERE.
Just as certain COVID-19 vaccines may be better suited for certain groups of people, certain COVID-19 vaccine stocks may be better suited for different investing styles. So, of the six leaders or potential leaders in the U.S. COVID-19 vaccine space right now, which may be the best pick for conservative investors and which may be the best pick for aggressive…
The small-cap biotech company featured in today’s article experienced a remarkable rally over the last few months. However, with the FDA having just approved its most advanced asset, a treatment for ADHD, the author believes that this “exhausts the company’s largest catalyst, and [they] do not see any material new catalysts any time soon.” With that, and with doubts about…
Among the four biotech stocks that may be worth considering this month highlighted in today’s article is a company focused on developing genetic therapies with the potential to restore, improve and preserve high-acuity physiological hearing for people living with certain forms of disabling hearing loss. For more on this company and the other three biotech stocks featured, CLICK HERE.
“The company highlighted in today’s article “helps its customers to find the exceedingly rare cells/antibodies needed to fight cancer, inflammation etc. Basically, to find the needle in the haystack” – and as it operates in a high-growth and rapidly expanding area of biotech, the author believes that this digital cell biology company is a solid candidate for high-growth/high-risk portfolios. For…
“It’s a small cap, a billion-dollar company, 100% revenue growth, and it’s small and it’s unknown,” says the author of today’s article of the pharmaceutical marketing company he highlights, which is disrupting the way that drugs are traditionally sold to physicians – and has become a multi-bagger stock in the process. For more on this “under-the-radar pic for investors who…have…
“While more suited for aggressive investors, and with the number of new traders skyrocketing over the past year and making good ideas to trade even harder to find, these could prove exciting additions for traders looking for solid alpha potential,” says the author of today’s article of the five Buy-rated energy stocks trading under $10 that he proceeds to highlight.…
In the biotech realm, the author of today’s article notes that “PDUFA (Prescription Drug User Fee Act) dates – the deadline of the FDA’s review of new drugs – determine whether a treatment is fit for purpose or not and a yay or nay can act as a major catalyst to send shares either soaring or crashing.” As such, he…
Of the four stocks highlighted in today’s article, the author declares them “outstanding ideas for aggressive growth investors looking to add this hot technology silo.” The silo in question? Cybersecurity and analytics, which, in a new research report, Goldman Sachs is very positive on. For four top new trends in cybersecurity and analytics that Goldman noted in its report, as…
While large-cap stocks receive more attention from analysts and more investment, the author of today’s article reminds the reader that “small caps, over time, outperform their larger peers.” With that, she proceeds to highlight three small-cap stocks that are showing strong technical performance – including, in the biotech arena, a genetic-testing specialist. For more, CLICK HERE.